Compare iShares Gold Trust (IAU) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Natera Inc. Common Stock — how do they compare? iShares Gold Trust trades at $78.03 (market cap $60.87B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: iShares Gold Trust and Natera Inc. Common Stock are close in size by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 51 Days and Natera Inc. Common Stock for 0 Days on average.
| IAU | NTRA | |
|---|---|---|
Market Cap | $60.87B | $57.03B |
Volume | 4,734,029 | 1,131,157 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $425.64 |
52-Week Low | $74.21 | $179.42 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU shares are trading at $78.25, down 0.11% with bearish technical signals dominating the short-term outlook. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent soft inflation data has provided some support. Technical indicators show selling pressure outweighing buying signals, with moving averages pointing downward and key resistance at $79.
The stock faces headwinds from monetary policy uncertainty and yield pressures, but potential exists if inflation concerns resurface. Key risks include continued rate hike expectations and dollar strength, while opportunities may emerge from safe-haven demand during market volatility. The technical setup suggests caution in the near term with support at $78.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
